EGRX Eagle Pharmaceuticals Inc.

+0.36  (+0%)
Previous Close 75.65
Open 75.6
Price To Book 6.33
Market Cap 1127641642
Shares 14,835,438
Volume 428,328
Short Ratio 8.96
Av. Daily Volume 245,324

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Pivotal trial initiation announced December 7, 2017. Data due fall of 2018.
Breast cancer
Tentative approval announced October 27, 2017. Full approval pending patent litigation with Eli Lilly.
Nonsquamous Non-Small Cell Lung Cancer (NSCLC) and Mesothelioma
CRL issued July 26, 2017. Additional trial required.
Exertional heat stroke (EHS)
Tentative approval July 2 2014. Teva has also received orphan drug and related pediatric exclusivity expiring in September 2015 and May 2016 for the CLL and NHL indications, respectively.
EP-3101 (bendamustine RTD)
Chronic lymphocytic leukemia; Indolent non-Hodgkin's lymphoma - cancer
CRL March 18 2016. FDA requested further characterization of bivalirudin-related substances in the drug product
KANGIO (bivalirudin injection)
Percutaneous Coronary Intervention (PCI) and Percutaneous Transluminal Coronary Angioplasty (PTCA)
Approved December 24, 2015.
Docetaxel Injection
Breast, non-small cell lung, prostate gastric adenocarcinoma, and head and neck cancer
Approved July 22, 2014 under priority review.
Malignant hyperthermia - cancer

Latest News

  1. Teva’s Key Drugs in Its Specialty Products Pipeline
  2. Benzinga Pro's 5 Stocks To Watch Today
  3. Teva Stock Could Jump after Good News from Partner Manufacturers
  4. Court Issues Decision in Favor of Eagle Pharmaceuticals Granting Seven Year Orphan Drug Exclusivity for BENDEKA (bendamustine hydrochloride injection)
  5. Eagle Pharmaceuticals, Inc. to Present at Investor Conferences in June
  6. Wired News – FDA Granted Approval to Eagle Pharma’s Bendamustine Hydrochloride RTD Solution in a 500ml Admixture
  7. Market Trends Toward New Normal in Agios Pharmaceuticals, Corcept Therapeutics, Prestige Brand, Virtu Financial, Eagle Pharmaceuticals, and Century Aluminum — Emerging Consolidated Expectations, Analyst Ratings
  8. Eagle Pharmaceuticals, Inc. Granted Final FDA Approval for Bendamustine Hydrochloride Ready-to-Dilute Solution in a 500ml Admixture
  9. Edited Transcript of EGRX earnings conference call or presentation 10-May-18 12:30pm GMT
  10. Eagle Pharmaceuticals: 1Q Earnings Snapshot
  11. Eagle Pharmaceuticals, Inc. Reports First Quarter 2018 Results
  12. New Strong Sell Stocks for May 2nd
  13. Eagle Pharmaceuticals, Inc. to Discuss First Quarter 2018 Financial Results on May 10, 2018
  14. Eagle Pharmaceuticals, Inc. to Present at 43rd Annual Deutsche Bank Health Care Conference
  15. Eagle Pharmaceuticals’ Vasopressin ANDA Accepted for Filing by the FDA
  16. See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.
  17. Eagle Pharmaceuticals Announces New Patent for Eagle Biologics
  18. Blog Exposure - Mylan Plans to Launch Two New HIV Treatments in the US
  19. New Strong Sell Stocks for March 1st

SEC Filings

  1. 8-K - Current report 18890931
  2. 8-K - Current report 18838766
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 18823176
  4. 8-K - Current report 18820454
  5. DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material 18790067
  6. DEF 14A - Other definitive proxy statements 18790037
  7. 8-K - Current report 18755533
  8. 8-K - Current report 18716868
  9. 8-K - Current report 18702211
  10. 8-K - Current report 18671891